Premium
Knockdown of sal‐like 4 expression by small interfering RNA induces apoptosis in breast cancer cells
Author(s) -
Hesari Amireza,
Anoshiravani Ali Arash,
Talebi Samaneh,
Noruzi Somayye,
Mohammadi Rezvan,
Salarinia Reza,
Zare Reza,
Ghasemi Faezeh
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28214
Subject(s) - gene knockdown , small interfering rna , transfection , gene expression , cancer research , gene , microbiology and biotechnology , breast cancer , apoptosis , rna interference , biology , transcription factor , cancer cell , rna , cancer , genetics
Breast cancer is the most prevalent cancers worldwide and causes a significant amount of deaths annually. Spalt‐like transcription factor 4 is known as a transcription factor, which has an important role in the proliferation of cancerous cells. Small interfering RNA (siRNA) is a short‐chain molecule of 20 to 25 nucleotides that protrude on two sides of the 3′, two nucleotides. In this study, using a specific sequence of siRNA against the sequence of this gene, its activity is investigated in the cell line of breast cancer. The breast cancer cells (MCF‐7) were cultured and then, using a specific anti‐sal–like 4 (SALL4) siRNA, their toxic doses were determined. Then, the gene is transfected into the cell. Proliferation and expression of the SALL4 and BCL‐2 gene were measured using the real‐time polymerase chain reaction method. The specific concentration of siRNA IC 50 of the SALL4 gene was 40.35 nmole. Gene expression results indicated that the expression of the Bcl‐2 gene in the siRNA group was significantly reduced ( P < 0.05). SiRNA can increase the apoptosis of breast cancer cells by reducing the gene expression of SALL4 gene and Bcl‐2; it can be used as a novel targeted therapy. This strategy, in addition to increasing the specificity of the drug, also reduces the side effects when compared with conventional chemotherapy.